Please ensure Javascript is enabled for purposes of website accessibility

Teladoc Crushes Q3 Estimates

By Eric Volkman – Updated Oct 29, 2020 at 9:22AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

However, the hot telemedicine services provider is still loss-making.

A breakout stock of the coronavirus era, Teladoc Health (TDOC -5.33%) delivered a third quarter that trounced analyst estimates.

The period saw the telemedicine services specialist book just under $289 million in revenue, which was more than double the Q3 2019 figure, it reported on Wednesday. The company's net loss, however, deepened to $35.9 million, from the year-ago $20.3 million. On an adjusted basis, the latest shortfall was $0.13 per share.

Regardless, both numbers convincingly beat analyst expectations. On average, they predicted almost $282 million on the top line, and a much deeper adjusted per-share net loss of $0.32.

A Teladoc member using the company's interface.

Using the Teladoc interface. Image source: Teladoc Health.

Teladoc continues to benefit from the dramatic rise in popularity of remote videoconferencing services (in its specific case, doctor visits) during the ever-lengthening coronavirus pandemic. New client partnerships with companies and organizations such as Spain's telecom incumbent Telefonica and Johns Hopkins University have also helped boost revenue.

Additionally, "We are seeing significant market success and consistent growth in member visits throughout all of our commercial channels," CEO Jason Gorevic said.

Teladoc also proffered estimates for its current fourth quarter and the full fiscal year. It believes revenue for the latter will range from just over $1 billion to nearly $1.02 billion, with a per-share net loss of $1.32 to $1.36. 

Teladoc has attracted no small amount of criticism lately because of the announcement in August that it agreed to acquire Livongo Health in a deal valued at $18.5 billion. Some observers are concerned that Livongo is not a good fit, while others balk at the rich price the consistently loss-making Teladoc will be paying for its big new asset.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Livongo Health Inc and Teladoc Health. The Motley Fool has a disclosure policy.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.